Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 10.89M | 10.53M | 11.02M | 12.13M | 13.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.89M | 10.53M | 11.02M | 12.13M | 13.68M |
| Cost of Revenue | -161.86M | 80.88M | 64.44M | 59.13M | -100.88M |
| Gross Profit | 172.75M | -70.35M | -53.43M | -46.99M | 114.55M |
| SG&A Expenses | 31.65M | 29.20M | 28.29M | 21.71M | 22.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.01M | 110.08M | 92.73M | 80.83M | 77.46M |
| Operating Income | -100.12M | -99.55M | -81.72M | -68.70M | -63.79M |
| Income Before Tax | -97.06M | -93.02M | -76.73M | -65.33M | -57.49M |
| Income Tax Expenses | -4.06M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -93.00M | -93.02M | -76.73M | -65.33M | -57.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.00M | -93.02M | -76.73M | -65.33M | -57.49M |
| EBIT | -100.12M | -99.55M | -81.72M | -68.70M | -63.79M |
| EBITDA | -92.57M | -91.97M | -76.17M | -64.97M | -60.57M |
| EPS Basic | -0.42 | -0.43 | -0.38 | -0.34 | -0.31 |
| Normalized Basic EPS | -0.28 | -0.27 | -0.24 | -0.21 | -0.20 |
| EPS Diluted | -0.42 | -0.43 | -0.38 | -0.34 | -0.31 |
| Normalized Diluted EPS | -0.28 | -0.27 | -0.24 | -0.21 | -0.20 |
| Average Basic Shares Outstanding | 223.16M | 214.33M | 201.42M | 191.62M | 185.67M |
| Average Diluted Shares Outstanding | 223.16M | 214.33M | 201.42M | 191.62M | 185.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |